Form 424B3 InMed Pharmaceuticals
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20261001/AS22V22GZC2RVTZ2222B2ZYSDJA9EZ223282
Filed on: October 1, 2026
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Diabetic Retinopathy Market Set to Expand as Longer-Acting Anti-VEGF Biologics, Gene Therapies, and a Maturing Pipeline Reshape the Treatment Landscape Through 2036
- Lyme Disease Market: Steady Growth Ahead as Vaccine Candidates and Novel Preventive Therapies Advance Through 2034
- XRP Price Prediction: The $1.60 Test Meets Remittix’s PayFi App Rollout to 1,000 Testers
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
